Cargando…
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry
INTRODUCTION: Understanding prognosis, especially long-term outcome, in advanced nonsmall cell lung cancer (NSCLC) is crucial to inform patients, guide treatment and plan supportive and palliative care. METHODS: Prognostic factors influencing overall survival (OS) and progression-free survival (PFS)...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892864/ https://www.ncbi.nlm.nih.gov/pubmed/36180086 http://dx.doi.org/10.1183/13993003.01336-2022 |
_version_ | 1784881402448183296 |
---|---|
author | Metzenmacher, Martin Griesinger, Frank Hummel, Horst-Dieter Elender, Corinna Schäfer, Harald de Wit, Maike Kaiser, Ulrich Kern, Jens Jänicke, Martina Spring, Lisa Zacharias, Stefan Kaiser-Osterhues, Anja Groth, Annika Hipper, Annette Zaun, Gregor Dörfel, Steffen Güldenzoph, Björn Müller, Lothar Uhlig, Jens Thomas, Michael Sebastian, Martin Eberhardt, Wilfried E.E. |
author_facet | Metzenmacher, Martin Griesinger, Frank Hummel, Horst-Dieter Elender, Corinna Schäfer, Harald de Wit, Maike Kaiser, Ulrich Kern, Jens Jänicke, Martina Spring, Lisa Zacharias, Stefan Kaiser-Osterhues, Anja Groth, Annika Hipper, Annette Zaun, Gregor Dörfel, Steffen Güldenzoph, Björn Müller, Lothar Uhlig, Jens Thomas, Michael Sebastian, Martin Eberhardt, Wilfried E.E. |
author_sort | Metzenmacher, Martin |
collection | PubMed |
description | INTRODUCTION: Understanding prognosis, especially long-term outcome, in advanced nonsmall cell lung cancer (NSCLC) is crucial to inform patients, guide treatment and plan supportive and palliative care. METHODS: Prognostic factors influencing overall survival (OS) and progression-free survival (PFS) in 2082 patients with wild-type (WT)-NSCLC (629 M1a, 249 M1b, 1204 M1c) are reported. Patients were included in the prospective German CRISP registry recruiting in >150 centres. Analysis for pre-therapeutic factors was based on results from Cox proportional hazard models. RESULTS: Current M-descriptors of the Union for International Cancer Control-8 staging system were validated: M1a and M1b patients had significantly longer median time to events compared to M1c (OS/PFS 16.4/7.2 months, 17.8/6.7 months and 10.9/5.4 months, respectively). OS and PFS were influenced by number and location of metastatic organ systems. M1c and four or more metastatic organs involved had shorter OS and PFS than M1c with one to three organs (OS hazard ratio (HR) 1.69, p<0.001; PFS HR 1.81, p<0.001). M1b-liver metastases had shorter OS/PFS than M1b involving other organs (OS HR 2.70, p=0.006; PFS HR 2.48, p=0.007). Based on number of involved organs (orgsys) and liver metastases, two risk groups (low-risk: M1a, M1b-non-liver, M1c-1-3-orgsys-non-liver; high-risk: M1c-liver, M1b-liver, M1c-4+-orgsys) with significantly different prognoses could be amalgamated (median OS/PFS 14.3/6.5 months and 7.7/4.1 months, respectively). Other favourable factors were female gender and Eastern Cooperative Oncology Group stage 0, with age showing no impact. Those with T1- or N0-status were associated with longer OS than T2–4 or N2–3. CONCLUSION: In this large observational dataset, we further defined factors for outcome in WT-NSCLC, including increased number of involved metastatic organ systems and liver metastases, as those with overall poorer prognosis and reduced survival chance. |
format | Online Article Text |
id | pubmed-9892864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-98928642023-02-06 Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry Metzenmacher, Martin Griesinger, Frank Hummel, Horst-Dieter Elender, Corinna Schäfer, Harald de Wit, Maike Kaiser, Ulrich Kern, Jens Jänicke, Martina Spring, Lisa Zacharias, Stefan Kaiser-Osterhues, Anja Groth, Annika Hipper, Annette Zaun, Gregor Dörfel, Steffen Güldenzoph, Björn Müller, Lothar Uhlig, Jens Thomas, Michael Sebastian, Martin Eberhardt, Wilfried E.E. Eur Respir J Original Research Articles INTRODUCTION: Understanding prognosis, especially long-term outcome, in advanced nonsmall cell lung cancer (NSCLC) is crucial to inform patients, guide treatment and plan supportive and palliative care. METHODS: Prognostic factors influencing overall survival (OS) and progression-free survival (PFS) in 2082 patients with wild-type (WT)-NSCLC (629 M1a, 249 M1b, 1204 M1c) are reported. Patients were included in the prospective German CRISP registry recruiting in >150 centres. Analysis for pre-therapeutic factors was based on results from Cox proportional hazard models. RESULTS: Current M-descriptors of the Union for International Cancer Control-8 staging system were validated: M1a and M1b patients had significantly longer median time to events compared to M1c (OS/PFS 16.4/7.2 months, 17.8/6.7 months and 10.9/5.4 months, respectively). OS and PFS were influenced by number and location of metastatic organ systems. M1c and four or more metastatic organs involved had shorter OS and PFS than M1c with one to three organs (OS hazard ratio (HR) 1.69, p<0.001; PFS HR 1.81, p<0.001). M1b-liver metastases had shorter OS/PFS than M1b involving other organs (OS HR 2.70, p=0.006; PFS HR 2.48, p=0.007). Based on number of involved organs (orgsys) and liver metastases, two risk groups (low-risk: M1a, M1b-non-liver, M1c-1-3-orgsys-non-liver; high-risk: M1c-liver, M1b-liver, M1c-4+-orgsys) with significantly different prognoses could be amalgamated (median OS/PFS 14.3/6.5 months and 7.7/4.1 months, respectively). Other favourable factors were female gender and Eastern Cooperative Oncology Group stage 0, with age showing no impact. Those with T1- or N0-status were associated with longer OS than T2–4 or N2–3. CONCLUSION: In this large observational dataset, we further defined factors for outcome in WT-NSCLC, including increased number of involved metastatic organ systems and liver metastases, as those with overall poorer prognosis and reduced survival chance. European Respiratory Society 2023-02-02 /pmc/articles/PMC9892864/ /pubmed/36180086 http://dx.doi.org/10.1183/13993003.01336-2022 Text en Copyright ©The authors 2023. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Original Research Articles Metzenmacher, Martin Griesinger, Frank Hummel, Horst-Dieter Elender, Corinna Schäfer, Harald de Wit, Maike Kaiser, Ulrich Kern, Jens Jänicke, Martina Spring, Lisa Zacharias, Stefan Kaiser-Osterhues, Anja Groth, Annika Hipper, Annette Zaun, Gregor Dörfel, Steffen Güldenzoph, Björn Müller, Lothar Uhlig, Jens Thomas, Michael Sebastian, Martin Eberhardt, Wilfried E.E. Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry |
title | Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry |
title_full | Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry |
title_fullStr | Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry |
title_full_unstemmed | Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry |
title_short | Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry |
title_sort | prognostic factors in nonsmall cell lung cancer: insights from the german crisp registry |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892864/ https://www.ncbi.nlm.nih.gov/pubmed/36180086 http://dx.doi.org/10.1183/13993003.01336-2022 |
work_keys_str_mv | AT metzenmachermartin prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT griesingerfrank prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT hummelhorstdieter prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT elendercorinna prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT schaferharald prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT dewitmaike prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT kaiserulrich prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT kernjens prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT janickemartina prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT springlisa prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT zachariasstefan prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT kaiserosterhuesanja prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT grothannika prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT hipperannette prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT zaungregor prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT dorfelsteffen prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT guldenzophbjorn prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT mullerlothar prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT uhligjens prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT thomasmichael prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT sebastianmartin prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry AT eberhardtwilfriedee prognosticfactorsinnonsmallcelllungcancerinsightsfromthegermancrispregistry |